PCYOX1L作为卵巢癌铂耐药诊断标志物在诊断试剂盒制备中的应用

CN120738355BActive Publication Date: 2026-07-17CHONGQING MEDICAL & PHARMA COLLEGE
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CHONGQING MEDICAL & PHARMA COLLEGE
Filing Date
2025-07-22
Publication Date
2026-07-17

Smart Images

  • Figure CN120738355B_ABST
    Figure CN120738355B_ABST
Patent Text Reader

Abstract

本发明公开了一种PCYOX1L作为卵巢癌铂耐药诊断标志物在诊断试剂盒制备中的应用。经过研究发现，异戊烯半胱氨酸氧化酶1样蛋白(PCYOX1L)基因的高表达与卵巢癌铂耐药相关，且PCYOX1L的表达水平显著影响卵巢癌细胞的增殖与凋亡过程，且与病人预后呈显著负相关，可作为卵巢癌潜在的独立预后因子和治疗靶点，也是卵巢癌铂耐药的诊断标志物。
Need to check novelty before this filing date? Find Prior Art